All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Tailored Treatment Improves Outcomes Across Lung Cancer

May 11th 2022

The hallmarks of lung cancer diagnosis and treatment are evolving, evidenced by increases in minimally invasive surgery, and immunotherapy combinations, as well as targeted therapies for rare molecular subsets.

VB10.16 Plus Atezolizumab Elicits Responses in HPV16-Positive Cervical Cancer

May 10th 2022

The first-in-class, off-the-shelf therapeutic cancer vaccine VB10.16 in combination with atezolizumab generated positive responses in heavily pretreated patients with HPV16-positive advanced cervical cancer.

Nihilism Remains a Barrier to Effective Treatment Delivery in Pancreatic Cancer

May 10th 2022

Jonathan Mizrahi, MD, discusses updates from the meeting in pancreatic cancer and hepatocellular carcinoma, the growing role of immunotherapy in GI cancer, and the ‘watch and wait’ protocol seen in rectal cancer

Lower Rates of Negative Surgical Margins Found in Black Patients Vs White Patients with GI Tract Cancer

May 10th 2022

Rates of negative surgical margins and adequate lymphadenectomies were lower in Black patients with gastrointestinal tract cancer compared with White patients, according to data from a retrospective cohort study published in JAMA Network Open.

Teclistamab/Daratumumab Combo Delivers Promising ORR in Heavily Pretreated Relapsed/Refractory Myeloma

May 10th 2022

Paula Rodriguez-Otero, MD, PhD, discusses the rationale, design, and findings of the phase 1b TRIMM-2 trial assessing subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma.

Advancing Cancer Care Through Clinical Trials in a Community Oncology Setting

May 10th 2022

The American Cancer Society reported earlier this year that the risk of dying from cancer in the United States has decreased by 32% over the past 28 years, which translates to almost 3.5 million fewer cancer deaths.

Pembrolizumab Plus Chemoradiotherapy to Be Investigated as Bladder-Preservation Treatment in MIBC

May 10th 2022

Pembrolizumab plus concurrent chemoradiotherapy is being investigated as a potential therapy in patients with muscle-invasive bladder cancer.

Unmasking NETs Requires a Multifaceted Approach to Care

May 10th 2022

Eric Liu, MD, FACS, reviews treatment options, pitfalls of diagnoses, and the importance of involving specialists and advocates early in neuroendocrine tumors.

Abemaciclib Plus Endocrine Therapy Elicits Efficacy in High-Risk, HR+ Early Breast Cancer Regardless of Menopausal Status

May 10th 2022

The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.

Racial Disparities Revealed in Surgical Outcomes in Gastrointestinal Tract Cancer

May 9th 2022

Sajid A. Khan MD, FACS, FSSO, discusses findings from the study on racial disparities in surgical outcomes and quality of care for GI tract cancer, plus what issues need to be addressed to close the gap in care.

Nivolumab Plus Trastuzumab Deruxtecan Provides No Perceptible Clinical Benefit Over ADC Alone in Advanced HER2+ Breast Cancer

May 9th 2022

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

Novartis Suspends Production of Radioligand Therapy Agents in New Jersey and Italy

May 9th 2022

Pharmaceutical giant Novartis has temporarily halted radioligand therapy production at sites in Millburn, New Jersey, and Ivrea, Italy, citing potential quality issues in its manufacturing processes.

PARP Inhibitors Are Under Study as Treatment Options Beyond BRCA-Mutated Breast Cancer

May 9th 2022

Virginia G. Kaklamani, MD, discussed the emerging role of PARP inhibitors, practice-changing updates in HER2-positive breast cancer, the utilization of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, and the various therapeutic classes and their effects on care in triple-negative breast cancer.

Mount Sinai Researchers Develop Novel Method to Identify and Treat Aggressive Early-Stage Lung Cancers

May 9th 2022

Mount Sinai researchers have developed a novel method to identify aggressive early-stage lung cancers and target drugs known as aurora kinase inhibitors to tumors that are especially likely to respond to them.

Ibrutinib-Based Combination Therapy Displays Superior Efficacy Vs Monotherapy in MCL

May 9th 2022

Ibrutinib-based combination therapy demonstrated a higher overall response rate and longer progression-free survival compared with ibrutinib alone in patients with relapsed/refractory mantle cell lymphoma.

Tackling the Adverse Effects of Immunotherapy

May 9th 2022

Igor Puzanov, MD, MSCI, FACP, discusses the adverse effects associated with immunotherapy and how to manage them.

FDA-Approved CAR T-Cell Therapies Illuminate Advances in Multiple Myeloma

May 9th 2022

Noopur S. Raje, MD, discussed the presentation she gave at the 26th Annual International Congress on Hematologic Malignancies® on the CAR T-cell therapy product bb21217, other exciting myeloma treatments that were presented at ASH, and the need for increased treatment accessibility.

HER2 Expression Is a Key Determinant of Trastuzumab Deruxtecan Activity

May 8th 2022

HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.

Niraparib Improves or Maintains HRQOL in Metastatic Castration-Resistant Prostate Cancer

May 7th 2022

Niraparib was found to maintain or improve health-related quality of life in patients with advanced or metastatic castration-resistant prostate cancer, according to data from the final analysis of the phase 2 GALAHAD trial.

Adjuvant Abemaciclib Plus Endocrine Therapy Has Robust Efficacy in monarchE Cohort of High-Risk, HR+ Breast Cancer

May 6th 2022

The addition of adjuvant abemaciclib to endocrine therapy resulted in a clinically meaningful reduction in the risk of developing invasive disease, particularly incurable distant metastatic disease, in patients with high-risk, hormone receptor–positive, HER2-negative, early breast cancer who comprised cohort 1 of the phase 3 monarchE trial.